TABLE 4.

Reported adverse events by participants (n = 129)

Adverse events	Mild	Moderate	Severe	Life‐threatening /disabling	Total (%)
Amnesia (memory loss)	1	0	0	0	1 (0.78%)
Anorexia (lack of appetite)	0	1	0	0	1 (0.78%)
Anxiety	1	0	0	0	1 (0.78%)
Blurred vision	1	0	0	0	1 (0.78%)
Cognitive disturbance	0	0	1	0	1 (0.78%)
Concentration impairment	0	1	0	0	1 (0.78%)
Constipation	3	1	0	0	4 (3.10%)
Coordination/balance/speech	1	1	0	0	2 (1.55%)
Dizziness	0	2	1	0	3 (2.33%)
Dry mouth	1	0	0	0	1 (0.78%)
Fall	0	2	0	0	2 (1.55%)
Fatigue	0	0	2	0	2 (1.55%)
Headache	0	0	1	0	1 (0.78%)
Increased seizures	0	1	0	0	1 (0.78%)
Insomnia (inability to sleep)	0	0	0	1	1 (0.78%)
Nausea	3	0	0	0	3 (2.33%)
Somnolence (sleepy/drowsy)	0	4	0	0	4 (3.10%)
Spasticity	0	0	1	0	1 (0.78%)
Total	11 (8.53%)	13 (10.08%)	6 (4.65%)	1 (0.78%)	31 (24.03%)